AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Corporate Update Conference Call
March 09 2010 - 8:00AM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs,
will report fourth quarter and full year 2009 financial results
before the NASDAQ Global Market opens on Tuesday, March 16, 2010.
Subsequently, at 8:30 a.m. Eastern time (5:30 a.m. Pacific time),
Dr. Leslie Hudson, AVI's President and Chief Executive Officer, and
J. David Boyle II, AVI's Senior Vice President and Chief Financial
Officer, will host a conference call to discuss the fourth quarter
and full year 2009 financial results and to provide a corporate
update.
The conference call may be accessed by dialing 866.578.5771 for
domestic callers and 617.213.8055 for international callers. The
passcode for the call is 39302987 and please specify to the
operator that you would like to join the "AVI BioPharma fourth
quarter and full year 2009 earnings call." The conference call will
be webcast live under the events section of AVI's website at
www.avibio.com, and will be archived there following the call.
Please connect to AVI's website several minutes prior to the start
of the broadcast to ensure adequate time for any software download
that may be necessary.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
RNA-based drugs utilizing proprietary derivatives of its antisense
chemistry (morpholino-modified phosphorodiamidate oligomers or
PMOs) that can be applied to a wide range of diseases and genetic
disorders through several distinct mechanisms of action. Unlike
other RNA therapeutic approaches, AVI's antisense technology has
been used to directly target both messenger RNA (mRNA) and its
precursor (pre-mRNA), allowing for both up- and down-regulation of
targeted genes and proteins. AVI's RNA-based drug programs are
being evaluated for the treatment of Duchenne muscular dystrophy,
including an ongoing systemic Phase 1b/2 clinical trial of exon
skipping with AVI-4658. AVI's antiviral programs have demonstrated
promising outcomes in Ebola Zaire and Marburg Musoke virus
infections and may prove applicable to other viral targets such as
Junin, influenza, HCV or Dengue viruses. For more information,
visit www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: The statements that are not historical facts
contained in this release are forward-looking statements that
involve risks and uncertainties, including, but not limited to, the
results of research and development efforts, the results of
preclinical and clinical testing, the effect of regulation by the
FDA and other agencies, the impact of competitive products, product
development, commercialization and technological difficulties, and
other risks detailed in the company's Securities and Exchange
Commission filings.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024